-
Gulf's decades-long strategy of sporting investment rocked by Mideast war
-
Souped-up VPNs play 'cat and mouse' game with Iran censors
-
Attacked Russian tanker drifting toward Libya: Italian authorities
-
Coroner 'not satisfied' boxer Hatton intended to take own life
-
Stocks drop, as oil rises as Mideast war persists
-
Vanishing glacier on Germany's highest peak prompts ski lift demolition
-
Chuck Norris, roundhouse-kicking action star, dead at 86: family
-
Supreme leader says Iran dealt enemies 'dizzying blow'
-
Audi team principal Wheatley in shock exit after two races
-
Spurs boss Tudor hopes for 'nice surprises' in relegation fight
-
Arsenal must prove they are winners in League Cup final, says Arteta
-
Record-breaking heat wave grips western US
-
Liverpool showdown brings back 'beautiful memories' for PSG coach Luis Enrique
-
IRA bomb victims drop civil court claim against Gerry Adams
-
Ntamack returns for Toulouse to face France rival Jalibert
-
Trump calls NATO allies 'cowards' over Iran
-
French jihadist jailed for life for Islamic State crimes against Yazidis
-
Chuck Norris, action man who inspired endless memes, dead at 86: family
-
Action movie star Chuck Norris has died: family statement
-
England stars have 'last chance' to earn World Cup spots: Tuchel
-
League Cup final a 'big moment' for Man City, says Guardiola
-
Injured Ronaldo misses Portugal World Cup friendlies
-
Liverpool condemn 'cowardly' racist abuse of Konate
-
Far from war, global fuel frustrations mount
-
German auto exports to China plunged a third in 2025: study
-
Coach Valverde to leave Bilbao at end of season
-
'Decimated'? The Iranian leaders killed in Israeli-US war
-
Mistral chief calls for European AI levy to pay creatives
-
Liverpool suffer Salah blow in chase for Champions League
-
Mahuchikh soars to world indoor high jump gold, Hodgkinson cruises
-
Spain include Joan Garcia as one of four new call-ups
-
Salah ruled out of Liverpool's Brighton clash
-
Ship crews ration food in Iran blockade: seafarers
-
Kuwait refinery hit as Iran marks New Year under shadow of war
-
England recall Mainoo, Maguire for pre-World Cup matches
-
Jerusalem's Muslims despair as war shuts Al-Aqsa Mosque for Eid
-
'War has aged us': Lebanon's kids aren't alright
-
Snooker great O'Sullivan makes history with highest-ever break
-
Kuwait refinery hit as Iran says missile production 'no concern'
-
India to tackle global obesity with cheap fat-loss jabs
-
Somaliland centre saves cheetahs from trafficking to Gulf palaces
-
China swim sensation Yu, 13, beats multiple Olympic medallist
-
North Korean leader, daughter try out new tank
-
Israel strikes 'decimated' Iran as war roils markets
-
James ties NBA record for most regular-season games in latest milestone
-
Trump's Mideast muddle could play into Xi's hands at planned summit
-
Wembanyama lifts playoff-bound Spurs, Doncic and James fuel Lakers
-
Japan ski paradise faces strains of global acclaim
-
Vinicius, Real Madrid must prove consistency in Atletico derby
-
Kane credits Kompany's Bayern 'evolution' as treble beckons
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
D.Schneider--BTB